Syndax Pharmaceuticals announced the discontinuation of axatilimab's clinical development for idiopathic pulmonary fibrosis (IPF) after the drug failed to meet its primary endpoint in the Phase 2 MAXPIRe trial. This pipeline blow led to a significant drop in SNDX stock, as a key potential growth driver was removed, shifting focus entirely to its chronic GVHD pipeline.
Syndax Pharmaceuticals (SNDX) announced the cessation of axatilimab's development for idiopathic pulmonary fibrosis (IPF) due to the drug missing its primary endpoint in the Phase 2 MAXPIRe trial. This is a significant negative catalyst for SNDX, as the IPF indication represented a substantial market opportunity and a key part of its growth pipeline. The immediate impact is a sharp decline in the stock price, reflecting the loss of future revenue potential from this indication. While axatilimab is still being developed for chronic graft-versus-host disease (cGVHD) with partner Incyte (INCY), the IPF failure reduces the overall value proposition and diversification of Syndax's pipeline, making the company more reliant on the success of its cGVHD programs. For traders, this signals a re-evaluation of SNDX's long-term growth prospects and increased risk associated with its remaining pipeline assets.